CN102762213A - 增加对酪氨酸激酶抑制物的敏感度的方法和组合物 - Google Patents

增加对酪氨酸激酶抑制物的敏感度的方法和组合物 Download PDF

Info

Publication number
CN102762213A
CN102762213A CN2010800604001A CN201080060400A CN102762213A CN 102762213 A CN102762213 A CN 102762213A CN 2010800604001 A CN2010800604001 A CN 2010800604001A CN 201080060400 A CN201080060400 A CN 201080060400A CN 102762213 A CN102762213 A CN 102762213A
Authority
CN
China
Prior art keywords
egfr
mir
expression
mirna
enzyme inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800604001A
Other languages
English (en)
Chinese (zh)
Inventor
P·J·雷德曼
K·M·吉雷斯
F·C·卡里诺乌斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Western Australia
Original Assignee
University of Western Australia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2009905758A external-priority patent/AU2009905758A0/en
Application filed by University of Western Australia filed Critical University of Western Australia
Publication of CN102762213A publication Critical patent/CN102762213A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN2010800604001A 2009-11-24 2010-11-24 增加对酪氨酸激酶抑制物的敏感度的方法和组合物 Pending CN102762213A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2009905758A AU2009905758A0 (en) 2009-11-24 Method of Modulating Epidermal Growth Factor (EGF) Ligands
AU2009905758 2009-11-24
PCT/AU2010/001578 WO2011063456A1 (en) 2009-11-24 2010-11-24 Methods and compositions for increasing sensitivity to tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
CN102762213A true CN102762213A (zh) 2012-10-31

Family

ID=44065735

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2010800604035A Pending CN102762214A (zh) 2009-11-24 2010-11-24 表皮生长因子受体配体的调节
CN2010800604001A Pending CN102762213A (zh) 2009-11-24 2010-11-24 增加对酪氨酸激酶抑制物的敏感度的方法和组合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN2010800604035A Pending CN102762214A (zh) 2009-11-24 2010-11-24 表皮生长因子受体配体的调节

Country Status (9)

Country Link
US (2) US20130090366A1 (enExample)
EP (2) EP2521555B1 (enExample)
JP (2) JP2013511560A (enExample)
CN (2) CN102762214A (enExample)
AU (2) AU2010324530B2 (enExample)
CA (2) CA2781571A1 (enExample)
DK (1) DK2521555T3 (enExample)
ES (1) ES2608923T3 (enExample)
WO (2) WO2011063455A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108537001A (zh) * 2018-04-12 2018-09-14 华中科技大学鄂州工业技术研究院 一种预测用于治疗肝癌的特异性治疗药物的方法

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2808389A1 (en) 2004-11-12 2014-12-03 Asuragen, Inc. Methods and compositions involving MIRNA and MIRNA inhibitor molecules
WO2012005572A1 (en) * 2010-07-06 2012-01-12 Interna Technologies Bv Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
JP6342329B2 (ja) * 2011-11-25 2018-06-13 アンテグラジャンＩｎｔｅｇｒａｇｅｎ Ｅｇｆｒ阻害剤による治療に対する応答性を予測するための方法
FR2984168B1 (fr) * 2011-12-19 2019-07-05 Chanel Parfums Beaute Micro-rna pour leur utilisation dans la pigmentation
WO2013173500A2 (en) * 2012-05-15 2013-11-21 New York University Method for predicting recurrence of melanoma using mirna alterations
CN104994861B (zh) * 2012-10-18 2019-10-11 西澳大学 使用miRNA的癌症疗法
US20140308274A1 (en) * 2013-03-15 2014-10-16 Mirna Therapeutics, Inc. Combination cancer treatments utilizing synthetic oligonucleotides and egfr-tki inhibitors
JP2016519076A (ja) * 2013-03-15 2016-06-30 ミルナ セラピューティクス，インク． マイクロｒｎａ及びｅｇｆｒ−ｔｋｉ阻害剤を利用する癌の併用処置
EP3027225B1 (en) 2013-07-31 2021-03-24 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating thermogenesis using transforming growth factor alpha

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008025073A1 (en) * 2006-08-28 2008-03-06 The University Of Western Australia Method of modulation of expression of epidermal growth factor receptor (egfr) involving mirna
WO2008073922A2 (en) * 2006-12-08 2008-06-19 Asuragen, Inc. Functions and targets of let-7 micro rnas

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1797183B1 (en) * 2004-09-02 2012-08-01 Yale University Regulation of oncogenes by micrornas
EP2808389A1 (en) * 2004-11-12 2014-12-03 Asuragen, Inc. Methods and compositions involving MIRNA and MIRNA inhibitor molecules
WO2008089388A2 (en) * 2007-01-19 2008-07-24 Bayer Healthcare Llc Treatment of cancers having resistance to chemotherapeutic agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008025073A1 (en) * 2006-08-28 2008-03-06 The University Of Western Australia Method of modulation of expression of epidermal growth factor receptor (egfr) involving mirna
WO2008073922A2 (en) * 2006-12-08 2008-06-19 Asuragen, Inc. Functions and targets of let-7 micro rnas

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
20080515: "microRNA-7 Inhibits the Epidermal Growth Factor Receptor and the Akt Pathway and Is Down-regulated in Glioblastoma", 《CANCER RESEARCH》 *
REBECCA J. WEBSTER等: "Regulation of Epidermal Growth Factor Receptor Signaling in Human Cancer Cells by MicroRNA-7", 《THE JOURNAL OF BIOLOGICAL CHEMISTRY》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108537001A (zh) * 2018-04-12 2018-09-14 华中科技大学鄂州工业技术研究院 一种预测用于治疗肝癌的特异性治疗药物的方法
CN108537001B (zh) * 2018-04-12 2021-06-01 华中科技大学鄂州工业技术研究院 一种预测用于治疗肝癌的特异性治疗药物的方法

Also Published As

Publication number Publication date
EP2504014A1 (en) 2012-10-03
AU2010324530B2 (en) 2016-12-15
WO2011063456A1 (en) 2011-06-03
CN102762214A (zh) 2012-10-31
JP2013511559A (ja) 2013-04-04
CA2781572A1 (en) 2011-06-03
ES2608923T3 (es) 2017-04-17
US20130090366A1 (en) 2013-04-11
EP2521555B1 (en) 2016-09-28
JP2013511560A (ja) 2013-04-04
AU2010324530A1 (en) 2012-07-19
US9051551B2 (en) 2015-06-09
EP2504014A4 (en) 2013-04-17
WO2011063455A1 (en) 2011-06-03
US20130116299A1 (en) 2013-05-09
AU2010324529A1 (en) 2012-07-19
EP2521555A1 (en) 2012-11-14
EP2521555A4 (en) 2013-08-07
DK2521555T3 (en) 2017-01-09
CA2781571A1 (en) 2011-06-03

Similar Documents

Publication Publication Date Title
CN102762213A (zh) 增加对酪氨酸激酶抑制物的敏感度的方法和组合物
Luo et al. Side population cells from human melanoma tumors reveal diverse mechanisms for chemoresistance
Shi et al. Functional differences of miR-125b on the invasion of primary glioblastoma CD133-negative cells and CD133-positive cells
CN107115352A (zh) 微rna和包含微rna的组合物
Cioffi et al. MicroRNA-21 overexpression contributes to vestibular schwannoma cell proliferation and survival
Nardella et al. Down-regulation of the Lamin A/C in neuroblastoma triggers the expansion of tumor initiating cells
Guo et al. Downregulation of VMP1 confers aggressive properties to colorectal cancer
US20140045924A1 (en) Melanoma treatments
Nakashiro et al. Identification of Akt1 as a potent therapeutic target for oral squamous cell carcinoma
CN108660212B (zh) Wdr1基因在制备非小细胞肺癌治疗和检测产品中的应用
US9745578B2 (en) Targeting microRNA miR-409-3P to treat prostate cancer
Wei et al. Tumor‐suppressive miR‐323a inhibits pancreatic cancer cell proliferation and glycolysis through targeting HK‐2
Andre et al. In vivo knockdown of CXCR4 using jetPEI/CXCR4 shRNA nanoparticles inhibits the pulmonary metastatic potential of B16-F10 melanoma cells
CN101096670B (zh) 干扰人甲胎蛋白基因的siRNA及重组腺病毒
CN111617248B (zh) Rfpl1s-201在制备抑制卵巢癌增殖、侵袭和/或转移的药物中的应用
CA2889020A1 (en) Treatment of metastatic breast cancer
CN100386435C (zh) 抑制多效生长因子基因表达的小干扰rna及其应用
CN103937800A (zh) 靶向多基因的siRNA分子及其抑制肿瘤的应用
CN103800918A (zh) 一种微小rna在制备抗肿瘤的药物中的应用
CN115052590A (zh) 包含8-氧代鸟嘌呤的RNA干扰诱导核酸、与包含8-氧代鸟嘌呤的microRNA结合的修饰的核酸及它们的用途
Hei et al. Circular RNA_0076977 contributes to oral squamous cell carcinoma progression through mediating microRNA-802 axis
Gu et al. RNAi-mediated knockdown of vascular endothelial growth factor inhibits vascularization and tumor growth in renal cell carcinoma
CN119220679A (zh) Dicer及其调控miRNA作为标志物在制备诊断、预防和/或治疗肿瘤肝转移的产品中的应用
Zhang Identification of genes associated with pancreatic cancer metastasis by CRISPR/Cas9 screening
Zhou The role of ADAM9 in triple-negative breast cancer progression

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20121031